Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

1. The podocyte: glomerular sentinel at the crossroads of innate and adaptive immunity.Frontiers in immunology · 2023
   Review
2. Overexpression of CD86 enhances the ability of THP-1 macrophages to defend against Talaromyces marneffei.Immunity, inflammation and disease · 2022
   Article
3. Dual Costimulatory and Coinhibitory Targeting with a Hybrid Fusion Protein as an Immunomodulatory Therapy in Lupus Nephritis Mice Models.International journal of molecular sciences · 2022
   Article
4. Losartan Protects Podocytes against High Glucose-induced Injury by Inhibiting B7-1 Expression.Current medical science · 2021
   Article
5. Dual and Opposite Costimulatory Targeting with a Novel Human Fusion Recombinant Protein Effectively Prevents Renal Warm Ischemia Reperfusion Injury and Allograft Rejection in Murine Models.International journal of molecular sciences · 2021
   Article
6. CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.BioMed research international · 2021
   Review
7. Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity.Kidney international reports · 2020
   Article
8. Podocyte-specific knockout of the neonatal Fc receptor (FcRn) results in differential protection depending on the model of glomerulonephritis.PloS one · 2020
   Article
9. The utility of urinary CD80 as a diagnostic marker in patients with renal diseases.Scientific reports · 2018
   Article
10. The role of B7-1 in proteinuria of glomerular origin.Nature reviews. Nephrology · 2018
    Review
11. Interaction of CD80 with Neph1: a potential mechanism of podocyte injury.Clinical and experimental nephrology · 2018
    Article
12. Podocyte-actin dynamics in health and disease.Nature reviews. Nephrology · 2016
    Review
13. Podocytes.F1000Research · 2016
    Review
14. In IgA Nephropathy, Glomerulosclerosis Is Associated with Increased Urinary CD80 Excretion and Urokinase-Type Plasminogen Activator Receptor-Positive Podocyturia.Nephron extra
    Article

Corrections and comments

• Comment on
  B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy.2016

Authors and funding

1 author at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as